JP2006517415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517415A5 JP2006517415A5 JP2006508590A JP2006508590A JP2006517415A5 JP 2006517415 A5 JP2006517415 A5 JP 2006517415A5 JP 2006508590 A JP2006508590 A JP 2006508590A JP 2006508590 A JP2006508590 A JP 2006508590A JP 2006517415 A5 JP2006517415 A5 JP 2006517415A5
- Authority
- JP
- Japan
- Prior art keywords
- homogenate
- broth
- polypeptide
- lactate
- addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 35
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 11
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 229960004189 ethacridine lactate Drugs 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 8
- 229960001588 ethacridine Drugs 0.000 claims 5
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 claims 5
- 239000012560 cell impurity Substances 0.000 claims 4
- 235000014655 lactic acid Nutrition 0.000 claims 4
- 239000004310 lactic acid Substances 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 14
- 108010076504 Protein Sorting Signals Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 101150009573 phoA gene Proteins 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- -1 BIOGEL HT® Chemical compound 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101100082540 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) pcp gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 101150088787 deoC2 gene Proteins 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 101150012518 lamB gene Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 101150074251 lpp gene Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 101150073640 ompF gene Proteins 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43941803P | 2003-01-09 | 2003-01-09 | |
| PCT/US2004/000499 WO2004092393A1 (en) | 2003-01-09 | 2004-01-08 | Purification of polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517415A JP2006517415A (ja) | 2006-07-27 |
| JP2006517415A5 true JP2006517415A5 (enExample) | 2006-11-16 |
Family
ID=33299572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508590A Withdrawn JP2006517415A (ja) | 2003-01-09 | 2004-01-08 | ポリペプチドの精製 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7169908B2 (enExample) |
| EP (1) | EP1581644B1 (enExample) |
| JP (1) | JP2006517415A (enExample) |
| KR (1) | KR20050095605A (enExample) |
| CN (1) | CN100467611C (enExample) |
| AT (1) | ATE364092T1 (enExample) |
| AU (1) | AU2004230670B2 (enExample) |
| BR (1) | BRPI0406470A (enExample) |
| CA (1) | CA2511946A1 (enExample) |
| DE (1) | DE602004006831T2 (enExample) |
| DK (1) | DK1581644T3 (enExample) |
| ES (1) | ES2287687T3 (enExample) |
| MX (1) | MXPA05007378A (enExample) |
| NZ (1) | NZ540895A (enExample) |
| PL (1) | PL377653A1 (enExample) |
| RU (1) | RU2337968C2 (enExample) |
| WO (1) | WO2004092393A1 (enExample) |
| ZA (1) | ZA200504990B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2158923E (pt) | 1998-08-06 | 2013-06-04 | Univ Duke | Conjugados de peg-urato oxidase e sua utilização |
| EP2292637B1 (en) * | 2002-09-06 | 2016-01-06 | Genentech, Inc. | Process for protein extraction |
| ES2538357T3 (es) | 2005-04-11 | 2015-06-19 | Crealta Pharmaceuticals Llc | Formas variantes de urato oxidasa y uso de las mismas |
| TWI418564B (zh) * | 2005-04-11 | 2013-12-11 | Savient Pharmaceuticals Inc | 利用陽離子界面活性劑之蛋白質純化 |
| EP1973942B1 (en) | 2005-12-22 | 2011-02-09 | Genentech, Inc. | Recombinant production of heparin binding proteins |
| EP2013225B1 (en) * | 2006-04-12 | 2014-12-17 | Crealta Pharmaceuticals LLC | Purification of proteins with cationic surfactant |
| FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
| CN101506222B (zh) | 2006-07-14 | 2013-10-02 | 健泰科生物技术公司 | 重组蛋白的重折叠 |
| US8569464B2 (en) * | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
| US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
| US8268586B2 (en) * | 2006-12-21 | 2012-09-18 | Novozymes, Inc. | Modified messenger RNA stabilizing sequences for expressing genes in bacterial cells |
| WO2008079302A2 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
| KR101431856B1 (ko) | 2007-01-22 | 2014-08-27 | 제넨테크, 인크. | 항체의 고분자전해질 침전 및 정제 |
| PL4365189T3 (pl) | 2007-07-09 | 2025-05-26 | F. Hoffmann-La Roche Ag | Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów |
| US7887821B2 (en) * | 2007-12-20 | 2011-02-15 | Alk-Abello A/S | Process for producing an allergen extract |
| WO2009151514A1 (en) | 2008-06-11 | 2009-12-17 | Millipore Corporation | Stirred tank bioreactor |
| GB0818228D0 (en) * | 2008-10-06 | 2008-11-12 | Avecia Biolog Ltd | Purification process |
| EP2337787A1 (en) * | 2008-10-17 | 2011-06-29 | Percivia LLC. | Clarification process |
| CN105037535A (zh) | 2008-12-16 | 2015-11-11 | Emd密理博公司 | 搅拌槽反应器及方法 |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| KR101858598B1 (ko) * | 2010-02-01 | 2018-05-16 | 디그나 비오테크, 에스.엘. | 인터페론 알파 5의 제조방법 |
| BR112012019848B1 (pt) * | 2010-02-12 | 2022-03-15 | LETI Pharma S.L. | Processo para produção de um extrato de alérgeno, extrato de alérgeno despigmentado polimerizado, composição farmacêutica, e vacina |
| WO2011110598A1 (en) * | 2010-03-10 | 2011-09-15 | F. Hoffmann-La Roche Ag | Method for purifying immunoglobulin solutions |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| KR101551295B1 (ko) | 2010-05-17 | 2015-09-08 | 이엠디 밀리포어 코포레이션 | 생체분자 정제용 자극 반응성 중합체 |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| DE102011001743A1 (de) * | 2011-04-01 | 2012-10-04 | Technische Universität Dortmund | Verfahren zur Trennung/Reinigung von Biomolekühlen |
| JP6216321B2 (ja) | 2011-10-11 | 2017-10-18 | ジェネンテック， インコーポレイテッド | 二重特異性抗体の構築の改善 |
| CN102443055B (zh) * | 2011-10-26 | 2017-07-28 | 浙江海正药业股份有限公司 | 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺 |
| KR102065355B1 (ko) * | 2012-05-31 | 2020-01-13 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 단백질 제조물 내의 응집체 양 감소를 위한 혼합 다관능 표면들의 사용 방법 |
| CN102701501A (zh) * | 2012-06-26 | 2012-10-03 | 天津市津华盛生物科技有限公司 | 工业乳酸链球菌素废水综合利用的方法 |
| WO2014123485A1 (en) * | 2013-02-06 | 2014-08-14 | Agency For Science, Technology And Research | Protein purification methods |
| WO2014133458A1 (en) * | 2013-02-26 | 2014-09-04 | Agency For Science, Technology And Research | Protein purification in the presence of nonionic organic polymers and electropositive surfaces |
| CN105189530B (zh) * | 2013-02-28 | 2019-06-07 | 新加坡科技研究局 | 从缺乏染色质的细胞培养收获物中色谱纯化抗体 |
| US10253063B2 (en) | 2013-02-28 | 2019-04-09 | Agency For Science, Technology And Research | Protein purification in the presence of nonionic organic polymers at elevated conductivity |
| RU2646098C2 (ru) * | 2013-04-30 | 2018-03-01 | Интас Фармасьютикалс Лтд | Новый способ клонирования, экспрессии и очистки для получения ранибизумаба |
| US10259841B2 (en) | 2014-04-30 | 2019-04-16 | Novozymes A/S | Method for reducing the DNA content of a fermentation broth |
| JP2019535819A (ja) | 2016-11-11 | 2019-12-12 | ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ | プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用 |
| CN108333263A (zh) * | 2017-01-20 | 2018-07-27 | 北京蛋白质组研究中心 | 一种尿蛋白制备方法及尿蛋白质组的检测方法 |
| TW201927335A (zh) * | 2017-10-02 | 2019-07-16 | 美商拜耳保健有限責任公司 | 防止雙硫鍵於細胞培養收集物中還原之方法 |
| WO2019126123A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| CN111363024A (zh) * | 2018-12-26 | 2020-07-03 | 深圳翰宇药业股份有限公司 | 多肽的纯化方法 |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| US20220228195A1 (en) * | 2019-06-05 | 2022-07-21 | Viome Life Science, Inc. | Sample collection methods and devices |
| ES3036955T3 (en) | 2020-04-15 | 2025-09-26 | Genentech Inc | Copper loss mitigation |
| CN112708566A (zh) * | 2021-01-25 | 2021-04-27 | 西南林业大学 | 一种黑曲霉生产胞外多聚物的优化培养基及培养方法 |
| CN114774500A (zh) * | 2022-04-26 | 2022-07-22 | 成都蜀星饲料有限公司 | 多肽及制备方法、有机复合微量元素及制备方法 |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL34079A (en) * | 1969-04-01 | 1973-02-28 | Upjohn Co | Purification of ypsilon-globulins |
| US3607857A (en) * | 1970-03-03 | 1971-09-21 | Upjohn Co | Process of removing acrinol from gamma globulin using siliceous material such as silica gel |
| US3903254A (en) * | 1971-07-23 | 1975-09-02 | Upjohn Co | Separation of erythrocyte stroma from lysing medium and hemoglobin with acrinol |
| DE2308013A1 (de) * | 1973-02-17 | 1974-09-12 | Behringwerke Ag | Katalasearme glucoseoxidase und verfahren zu ihrer gewinnung |
| JPS519035B2 (enExample) | 1973-10-31 | 1976-03-23 | ||
| SU944580A1 (ru) | 1980-02-07 | 1982-07-23 | Кировский научно-исследовательский институт переливания крови | Способ получени поверхностного антигена гепатита В |
| US4563303A (en) * | 1984-04-14 | 1986-01-07 | Judicial Foundation The Chemosero-Therapeutic Research Institute | Method for purification of filamentous hemagglutinin |
| JPS60258127A (ja) | 1984-06-04 | 1985-12-20 | Green Cross Corp:The | Ｂ型肝炎ワクチンの製造方法 |
| WO1986007093A1 (fr) | 1985-05-29 | 1986-12-04 | The Green Cross Corporation | Procede de preparation d'une proteine heterogene |
| DE3581412D1 (de) | 1985-07-16 | 1991-02-21 | Green Cross Corp | Verfahren zur herstellung von heteroproteinen. |
| DE3604947A1 (de) | 1986-02-17 | 1987-08-20 | Biotest Pharma Gmbh | Verfahren zur herstellung eines immunglobulinhaltigen praeparates und dessen verwendung zur prophylaxe und therapie von aids |
| FR2600078B1 (fr) | 1986-06-12 | 1989-07-13 | Merieux Inst | Procede de preparation de facteur xiii a partir du placenta |
| DE3929504A1 (de) | 1989-09-06 | 1991-03-07 | Behringwerke Ag | Verfahren zur reinigung von plasminogen-aktivator-inhibitor 2 (pai-2) |
| DE4030264A1 (de) * | 1990-09-25 | 1992-04-23 | Hoechst Ag | Verfahren zur herstellung gereinigter glycolipide durch membrantrennverfahren |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US5861263A (en) * | 1992-10-20 | 1999-01-19 | Universidad Autonoma De Nuevo Leon | Preparation of preserved entamoeba histolytica antigens without enzymatic inhibitors and their use in immunological methods |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5760189A (en) | 1995-06-02 | 1998-06-02 | Genetics Institute, Inc. | Protein recovery & purification methods |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| ES2287976T3 (es) | 1997-06-13 | 2007-12-16 | Genentech, Inc. | Recuperacion de proteinas mediante cromatografia seguida de filtracion sobre una capa cargada. |
| JPH11341947A (ja) * | 1998-06-02 | 1999-12-14 | Yakult Honsha Co Ltd | 発酵管理方法 |
| US6156514A (en) * | 1998-12-03 | 2000-12-05 | Sunol Molecular Corporation | Methods for making recombinant cells |
| WO2001053335A2 (en) * | 2000-01-20 | 2001-07-26 | Regents Of The University Of Minnesota | Peptides with antibacterial activity |
-
2004
- 2004-01-08 DE DE602004006831T patent/DE602004006831T2/de not_active Expired - Lifetime
- 2004-01-08 DK DK04700878T patent/DK1581644T3/da active
- 2004-01-08 CA CA002511946A patent/CA2511946A1/en not_active Abandoned
- 2004-01-08 US US10/754,212 patent/US7169908B2/en not_active Expired - Fee Related
- 2004-01-08 EP EP04700878A patent/EP1581644B1/en not_active Expired - Lifetime
- 2004-01-08 NZ NZ540895A patent/NZ540895A/en not_active IP Right Cessation
- 2004-01-08 KR KR1020057012831A patent/KR20050095605A/ko not_active Ceased
- 2004-01-08 RU RU2005125210/13A patent/RU2337968C2/ru not_active IP Right Cessation
- 2004-01-08 WO PCT/US2004/000499 patent/WO2004092393A1/en not_active Ceased
- 2004-01-08 ZA ZA200504990A patent/ZA200504990B/en unknown
- 2004-01-08 AT AT04700878T patent/ATE364092T1/de active
- 2004-01-08 BR BR0406470-4A patent/BRPI0406470A/pt not_active Application Discontinuation
- 2004-01-08 MX MXPA05007378A patent/MXPA05007378A/es active IP Right Grant
- 2004-01-08 CN CNB2004800063965A patent/CN100467611C/zh not_active Expired - Fee Related
- 2004-01-08 PL PL377653A patent/PL377653A1/pl not_active Application Discontinuation
- 2004-01-08 JP JP2006508590A patent/JP2006517415A/ja not_active Withdrawn
- 2004-01-08 ES ES04700878T patent/ES2287687T3/es not_active Expired - Lifetime
- 2004-01-08 AU AU2004230670A patent/AU2004230670B2/en not_active Expired - Fee Related
-
2006
- 2006-12-12 US US11/609,529 patent/US7579448B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517415A5 (enExample) | ||
| US7169908B2 (en) | Purification of polypeptides | |
| JP2575604B2 (ja) | 沈澱異種蛋白質の精製及び活性化法 | |
| CA2220447C (en) | Novel fusion protein recovery and purification methods | |
| CA2656835C (en) | Refolding of recombinant proteins | |
| JPS60500893A (ja) | タンパク質の生産方法 | |
| WO1996014422A1 (en) | Process for bacterial production of heterologous polypeptides with disulphide bonds | |
| WO1998018946A1 (en) | Process for bacterial production of polypeptides | |
| JP2002528071A (ja) | 細菌性細胞からの異種ポリペプチドの回収方法 | |
| CN104379596B (zh) | 用于纯化重组恶性疟原虫环子孢子蛋白的方法 | |
| CN104144939A (zh) | 柱上酶切割 | |
| KR960003548B1 (ko) | 생물활성을 갖는 모노머성 성장호르몬의 분리방법 | |
| CN116640743A (zh) | 一种核酸内切酶及其应用 | |
| Ferré et al. | A novel system for continuous protein refolding and on‐line capture by expanded bed adsorption | |
| CN104263747A (zh) | 一种长效蛋白质药物表达复性修饰的双标签载体及方法 | |
| WO2024119434A1 (zh) | 一种提高重组蛋白表达效率的酸性表面助溶短肽标签 | |
| US6713611B2 (en) | Method for removing endotoxin from the samples containing basic protein | |
| RU2811436C1 (ru) | Рекомбинантная плазмида pETZ, обеспечивающая синтез и секрецию рекомбинантного белка A, и рекомбинантный белок A, используемый для иммунохимических анализов | |
| RU2821947C2 (ru) | Способ получения мембранного белка | |
| CN112210019A (zh) | 一种含单跨膜区的膜蛋白其跨膜区的纯化方法 | |
| CN119432916A (zh) | 一种趋化素Chemerin的功能活性体的制备方法及应用 | |
| CN117659212A (zh) | 一种表皮细胞生长因子的融合蛋白及其制备方法与应用 | |
| JPH0575760B2 (enExample) | ||
| US20210147477A1 (en) | Process for producing a membrane protein | |
| MANUAL | NEBExpress® MBP Fusion and Purification System |